CD8A and non-small cell lung carcinoma: In another study in NSCLC patients (n = 13), the same team described that PD-1+ CD8+ T cells activated by PD-1 therapy were mostly CD28+, suggesting a potential role for this costimulation molecule in ICB response (105).